Article
Oncology
Hyun Ae Jung, Miso Kim, Hae Su Kim, Joo-Hang Kim, Yoon Hee Choi, Jinhyun Cho, Ji Hyun Park, Keon Uk Park, Bo Mi Ku, Sehhoon Park, Jong -Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Summary: The study evaluated the efficacy and safety of Palbociclib monotherapy in patients with recurrent or refractory advanced thymic epithelial tumors (TETs). The results showed that Palbociclib monotherapy had good tolerability and encouraging efficacy in patients with TETs. However, there is currently no standard chemotherapy option for patients who fail platinum-based combination chemotherapy.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Fabio Conforti, Laura Pala, Grazia Vivanet, Chiara Corti, Chiara Catania, Daniele Maiettini, Gianluca Varano, Benedetta Di Venosa, Giuseppe Curigliano, Piermario Salvini, Rossana Berardi, Zelmira Ballatore, Tommaso Martino De Pas
Summary: The study investigated the efficacy and safety of high-dose continuous-infusion Ifosfamide in advanced thymoma and thymic carcinoma patients. The results demonstrated that high-dose continuous-infusion Ifosfamide showed significant clinical efficacy and good safety profile in patients with advanced thymic epithelial tumors.
Review
Oncology
Vanessa Nicoli, Fabio Coppede
Summary: Thymic epithelial tumors (TETs) arise from the epithelial cells of the thymus and account for 1% of all adult malignancies, despite being the most common lesions of the anterior mediastinum. TETs can be classified into different subtypes, including thymomas, thymic carcinomas, and neuroendocrine forms. The challenge lies in the diagnosis and characterization of TETs due to the lack of symptoms and the presence of paraneoplastic disorders. Epigenetic profiling has been explored as a potential tool for tumor characterization and clinical outcomes prediction.
Article
Medicine, General & Internal
Zhengbo Song, Guangyuan Lou, Yina Wang, Zhiping Yang, Wenxian Wang, Yongling Ji, Shiqing Chen, Chunwei Xu, Xiao Hu, Yiping Zhang
Summary: This study evaluated the efficacy and safety of apatinib in the treatment of advanced TETs. The results showed promising antitumor activity and manageable toxicity of apatinib in this patient population.
Article
Multidisciplinary Sciences
Zhongwei Xin, Mingjie Lin, Zhixing Hao, Di Chen, Yongyuan Chen, Xiaoke Chen, Xia Xu, Jinfan Li, Dang Wu, Ying Chai, Pin Wu
Summary: In this study, the developmental pattern of intra-tumoral T-cells in human thymic epithelial tumors (TET) was analyzed by single cell analysis. Three types of TETs were identified based on the characteristics of tumor cells and their effects on T-cell development. The molecular subtypes of TETs were found to determine their tumor immune microenvironment, and GNB3 and CHI3L1 might serve as predictors for the immunological behavior and prognosis of these tumors.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Chang-Lu Wang, Yi-Zhuo Zhao, Qin Zhang, Wan-Qin Zeng, Tian-Ying Jia, Lei Zhu, Wen-Tao Fang, Xiao-Long Fu
Summary: This retrospective study evaluated the efficacy and safety of anlotinib treatment for patients with relapsed and refractory thymic epithelial tumors (TETs). The results showed that anlotinib was active in patients with advanced TETs refractory to routine chemotherapy, but caution should be exercised when prescribing anlotinib to patients with myasthenia gravis.
Article
Medicine, General & Internal
M. R. Mirza, D. M. Chase, B. M. Slomovitz, R. dePont Christensen, Z. Novak, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L. M. Landrum, L. C. Hanker, A. Stuckey, I. Boere, M. A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. S. Shahin, S. E. Gill, B. J. Monk, J. Buscema, T. J. Herzog, L. J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R. L. Coleman, M. A. Powell
Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Biology
Elisabetta Kuhn, Carlo Pescia, Paolo Mendogni, Mario Nosotti, Stefano Ferrero
Summary: Despite their rarity, thymic epithelial tumors (TETs) have received substantial attention, leading to numerous histological and staging classifications. TETs are currently categorized into four main subtypes, each representing different aggressiveness. TNM and Masaoka-Koga staging systems are widely used for TETs. Additionally, molecular subgrouping has further enhanced the understanding of TETs and paved the way for targeted therapies and immune-checkpoint inhibitors.
Article
Biochemistry & Molecular Biology
Kostas Palamaris, Georgia Levidou, Katerina Kordali, Christos Masaoutis, Dimitra Rontogianni, Stamatios Theocharis
Summary: Immunohistochemical analysis of Hippo cascade components (YAP, TAZ, TEAD4 and LATS1) in thymic epithelial tumors (TETs) revealed associations between TAZ and TEAD4 with aggressive tumors and advanced stages, while YAP showed associations with indolent and earlier stage tumors. However, none of these components were significantly correlated with patient overall or disease-free survival.
Article
Oncology
Gabriele Antonarelli, Chiara Corti, Paolo Andrea Zucali, Matteo Perrino, Sara Manglaviti, Giuseppe Lo Russo, Gianluca Maria Varano, Piermario Salvini, Giuseppe Curigliano, Chiara Catania, Fabio Conforti, Tommaso De Pas
Summary: Continuous daily dosing (CDD) sunitinib showed significant antitumor activity and a manageable toxicity profile in platinum-resistant thymic epithelial tumors (TETs) patients. This study provides evidence for considering CDD sunitinib as a potential treatment option for TETs.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Guozhu Hou, Yuanyuan Jiang, Fang Li, Wuying Cheng
Summary: This study evaluated the diagnostic and prognostic value of FDG PET/CT in patients with suspected recurrent TETs. The results showed that FDG PET/CT had high sensitivity and good specificity in detecting recurrence, and it had important prognostic value in assessing the risk of disease progression.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Rohan Maniar, Patrick J. Loehrer
Summary: Thymic epithelial tumors (TETs) are rare malignancies originating from the thymus. Surgery is the primary treatment for early-stage TETs, while limited options with modest efficacy exist for unresectable, metastatic, or recurrent TETs. The emergence of immunotherapies in solid tumor treatment has sparked interest in their role in TET treatment. However, the occurrence of comorbid paraneoplastic autoimmune disorders, particularly in thymoma, has tempered expectations for immune-based therapies. Clinical studies of immune checkpoint blockade (ICB) in thymoma and thymic carcinoma have shown higher rates of immune-related adverse events (IRAEs) and limited efficacy. Despite setbacks, the understanding of the thymic tumor microenvironment and systemic immune system has advanced, leading to opportunities for novel immunotherapy approaches. Ongoing studies are evaluating various immune-based treatments in TETs to improve clinical efficacy and mitigate IRAE risk.
Review
Biology
Alfredo Tartarone, Rosa Lerose, Alessandro Rocco Lettini, Marina Tartarone
Summary: Thymic epithelial tumors (TETs) are unusual tumors deriving from the epithelial cells of the thymus and are the most common tumor type in the anterior mediastinum. Treatment options may vary based on staging and histology, including surgery with or without neoadjuvant or adjuvant therapy such as chemotherapy, radiotherapy, or a combination. Platinum-based chemotherapy is the standard first-line treatment for advanced or metastatic TETs, although new drugs and combinations are currently being evaluated. The proper management of TET patients requires a multidisciplinary team approach to personalize care for each patient.
Review
Oncology
Birte Ohm, Wolfgang Jungraithmayr
Summary: Treatment options for advanced thymic malignancies are limited. Immune checkpoint inhibitors are effective against thymic epithelial tumors, but carry a high risk of adverse events. This article aims to provide new insights on predictive markers for treatment efficacy and risk of adverse events, allowing for safe and precise clinical indications for immunotherapy in thymic malignancies.
Review
Oncology
Anja C. Roden
Summary: This article discusses the molecular aberrations in thymic epithelial tumors, specifically gene fusions, and explores their potential impact on diagnosis, tumor pathogenesis, and clinical treatment. Further research is needed to elucidate the molecular characteristics of these rare but aggressive tumors and optimize patient management and treatment.
Article
Oncology
Derek Brown, Adriana Zingone, Yunkai Yu, Bin Zhu, Julian Candia, Liang Cao, Brid M. Ryan
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2019)
Article
Hematology
Sencer Goklemez, Annie P. Im, Liang Cao, Filip Pirsl, Seth M. Steinberg, Lauren M. Curtis, Sandra A. Mitchell, Edward W. Cowen, Judy Baruffaldi, Jeremy Rose, Jacqueline Mays, Alen Ostojic, Noa G. Holtzman, Frances T. Hakim, Steven Z. Pavletic
AMERICAN JOURNAL OF HEMATOLOGY
(2020)
Article
Medicine, General & Internal
Goli Samimi, Brandy M. Heckman-Stoddard, Christine Holmberg, Bethany Tennant, Bonny Bloodgood Sheppard, Kisha I. Coa, Shelley S. Kay, Leslie G. Ford, Eva Szabo, Lori M. Minasian
AMERICAN JOURNAL OF MEDICINE
(2020)
Article
Oncology
Jung-Min Lee, Christina M. Annunziata, John L. Hays, Liang Cao, Peter Choyke, Minshu Yu, Daniel An, Ismail Baris Turkbey, Lori M. Minasian, Seth M. Steinberg, Helen Chen, John Wright, Elise C. Kohn
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Andrea B. Apolo, Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg, Liang Cao, Howard L. Parnes, Rene Costello, Maria J. Merino, Les R. Folio, Liza Lindenberg, Mark Raffeld, Jeffrey Lin, Min-Jung Lee, Sunmin Lee, Sylvia V. Alarcon, Akira Yuno, Nancy A. Dawson, Kimaada Allette, Arpita Roy, Dinuka De Silva, Molly M. Lee, Tristan M. Sissung, William D. Figg, Piyush K. Agarwal, John J. Wright, Yangmin M. Ning, James L. Gulley, William L. Dahut, Donald P. Bottaro, Jane B. Trepel
Article
Hematology
Lauren M. Curtis, Alen Ostojic, David J. Venzon, Noa G. Holtzman, Filip Pirsl, Zoya J. Kuzmina, Kristin Baird, Jeremy J. Rose, Edward W. Cowen, Jacqueline W. Mays, Sandra A. Mitchell, Laura Parsons-Wandell, Galen O. Joe, Leora E. Comis, Ann Berger, Iskra Pusic, Cody J. Peer, William D. Figg, Liang Cao, Robert Peter Gale, Frances T. Hakim, Steven Z. Pavletic
Summary: This study showed that pomalidomide is a safe and effective therapy for steroid-refractory chronic graft-versus-host disease, with particular efficacy in treating sclerotic skin manifestations. The primary endpoint was overall response rate at 6 months and change in body surface area involvement of skin cGVHD, showing promising results in improving the condition of patients with moderate to severe cGVHD.
Article
Oncology
Goli Samimi, Brandy M. Heckman-Stoddard, Christine Holmberg, Bethany Tennant, Bonny Bloodgood Sheppard, Kisha Coa, Shelley S. Kay, Leslie G. Ford, Eva Szabo, Lori M. Minasian
Summary: Primary care physicians (PCPs) play an important role in cancer prevention, but there is variability in their use and attitudes towards breast and ovarian cancer risk assessment and prevention interventions. A survey of PCPs in the United States showed that some were less familiar or cautious, leading to differences in prescribing behaviors. Improving the implementation of cancer risk assessment and clinical management guidelines within primary care may be necessary to address this variability and improve appropriate prescribing of cancer prevention interventions.
CANCER PREVENTION RESEARCH
(2021)
Article
Biophysics
Sencer Goklemez, Leorey N. Saligan, Filip Pirsl, Noa G. Holtzman, Alen Ostojic, Seth M. Steinberg, Frances T. Hakim, Jeremy J. Rose, Zhigang Kang, Yunkai Yu, Liang Cao, Sandra A. Mitchell, Annie Im, Steven Z. Pavletic
Summary: Limited information is available on the clinical and biological properties of fatigue in patients with chronic graft-versus-host disease (cGvHD). Fatigued patients showed correlations with walk velocity, NIH joint-fascia score, human activity profile, and SF-36 physical and mental health self-report scales. Higher rates of untreated depression and insomnia were reported in the fatigued group, emphasizing the need for clinical management of these conditions.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biochemistry & Molecular Biology
Jessica A. Canter, Sarah E. Ernst, Kristin M. Peters, Bradley A. Carlson, Noelle R. J. Thielman, Lara Grysczyk, Precious Udofe, Yunkai Yu, Liang Cao, Cindy D. Davis, Vadim N. Gladyshev, Dolph L. Hatfield, Petra A. Tsuji
Summary: The study suggests that Selenof may play a significant role in the development of colon tumors, affecting intestinal barrier integrity and the structural changes in glandular and mucin-producing goblet cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Yunkai Yu, Dominic Esposito, Zhigang Kang, Jianming Lu, Alan T. Remaley, Valeria De Giorgi, Leonard N. Chen, Kamille West, Liang Cao
Summary: Several variants of SARS-CoV-2 have emerged, some of which are associated with increased transmission and severity. Analyses of COVID-19 convalescent and diagnostic cohorts show that RBD antibody levels can serve as a good surrogate for neutralization activities. Individuals vaccinated with mRNA vaccines have significantly higher RBD antibody levels and similar neutralization activities compared to those naturally infected. This suggests that mRNA vaccination may generate more neutralizing RBD antibodies than natural immunity.
SCIENTIFIC REPORTS
(2022)
Editorial Material
Oncology
Goli Samimi, Jasmine Douglas, Brandy M. Heckman-Stoddard, Leslie G. Ford, Eva Szabo, Lori M. Minasian
Summary: The Division of Cancer Prevention in the NCI sponsored a Roundtable with primary care providers to discuss barriers and potential opportunities for integrating cancer prevention within primary care. The Roundtable focused on challenges and research opportunities related to cancer risk assessment, prevention interventions, electronic health records, and patient engagement. Time constraints and inconsistent clinical guidelines are major barriers, and research is needed to determine the best implementation methods across different communities and clinical settings.
CANCER PREVENTION RESEARCH
(2022)
Article
Oncology
Linda L. Garland, Jose Guillen-Rodriguez, Chiu-Hsieh Hsu, Lisa E. Davis, Eva Szabo, Christopher R. Husted, Hanqiao Liu, Ashley LeClerc, Yuriy O. Alekseyev, Gang Liu, Julie E. Bauman, Avrum E. Spira, Jennifer Beane, Malgorzata Wojtowicz, H. -H. Sherry Chow
Summary: Aspirin and zileuton have lung cancer prevention effects, but minimal effects on nasal gene expression related to smoking, lung cancer, and COPD. However, they do have a favorable effect on the gene expression related to squamous dysplasia. Continued investigation of leukotriene inhibitors is needed to confirm these findings and identify the safest, optimally dosed agents.
Article
Oncology
Guillaume Joe Pegna, Min-Jung Lee, Cody J. Peer, Mehwish Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine
Summary: The clinical trial of LMB-100 demonstrated some clinical efficacy but also revealed the potential intolerable side effect of capillary leak syndrome (CLS) when combined with nab-paclitaxel. Furthermore, LMB-100 treatment was found to cause systemic immune activation and associated inflammatory and immune changes.
Review
Oncology
Jens Eickhoff, Jen Zaborek, Guanhua Chen, Vikrant V. Sahasrabuddhe, Leslie G. Ford, Eva Szabo, KyungMann Kim
Summary: Early phase cancer prevention trials often fail to detect intervention effects. A systematic review of recently completed trials showed substantial differences between hypothesized and observed effect sizes, highlighting the need for careful planning of study design and sample size determination to detect meaningful intervention effects.
CANCER PREVENTION RESEARCH
(2023)
Article
Hematology
Alexander H. Yang, Ma Ai Thanda Han, Niharika Samala, Bisharah S. Rizvi, Rachel Marchalik, Ohad Etzion, Elizabeth C. Wright, Liang Cao, Frances T. Hakim, Elizabeth Jones, Devika Kapuria, Dennis D. Hickstein, Daniel Fowler, Jennifer A. Kanakry, Christopher G. Kanakry, David E. Kleiner, Christopher Koh, Steven Z. Pavletic, Theo Heller
Summary: Hepatic chronic graft-versus-host disease (cGVHD) is difficult to diagnose accurately, and current diagnostic criteria lack specificity. This study aimed to characterize different patterns of liver injury and cytokine profiles associated with hepatic dysfunction in cGVHD, evaluate the accuracy of the NIH Consensus Criteria (NCC) for hepatic cGVHD, and explore predictors for hepatic cGVHD. The results showed that abnormal liver enzymes in cGVHD are nonspecific and have poor correlation with histologic evidence for hepatic GVHD, emphasizing the importance of histology. Additionally, decreased platelet count was associated with factors associated with liver disease, suggesting disease progression.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)